Elicera Therapeutics (Q4 review): Important readout ahead - Redeye
Redeye returns with an update following Elicera’s Q4 earnings release. The numbers offered few surprises, which is typical for a pre-revenue biotech. What stands out is the upcoming data from the CARMA-study with ELC-301, expected in Q2.
ANNONS
Redeye returns with an update following Elicera’s Q4 earnings release. The numbers offered few surprises, which is typical for a pre-revenue biotech. What stands out is the upcoming data from the CARMA-study with ELC-301, expected in Q2.